vatalanib has been researched along with 11-cis-retinal in 1 studies
| Studies (vatalanib) | Trials (vatalanib) | Recent Studies (post-2010) (vatalanib) | Studies (11-cis-retinal) | Trials (11-cis-retinal) | Recent Studies (post-2010) (11-cis-retinal) |
|---|---|---|---|---|---|
| 276 | 42 | 98 | 7,289 | 4 | 2,014 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Campochiaro, PA; Hofmann, F; Okamoto, N; Ozaki, H; Ozaki, K; Seo, MS; Wood, JM; Yamada, E; Yamada, H | 1 |
1 other study(ies) available for vatalanib and 11-cis-retinal
| Article | Year |
|---|---|
Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization.
Topics: Aging; Angiogenesis Inhibitors; Animals; Animals, Newborn; Endothelial Growth Factors; Enzyme Inhibitors; Ischemia; Lymphokines; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neovascularization, Pathologic; Phosphotransferases; Phthalazines; Pyridines; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Retinal Vessels; Rhodopsin; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2000 |